Previous 10 | Next 10 |
2023-05-02 08:27:58 ET GD Culture Group Limited ( GDC ) -48% . Chegg ( CHGG ) -47% after Q1 earning release . UTime Limited ( UTME ) -34% . Aytu BioPharma ( AYTU ) -29% . Tantech Holdings ( TANH ) -26% announces full year 2022 ...
ENGLEWOOD, CO / ACCESSWIRE / May 1, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT M...
U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023 Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product Margins by an Estimated 1...
Aytu BioPharma, Inc. (AYTU) Q2 2023 Earnings Conference Call February 21, 2023 04:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim...
Aytu BioScience press release ( NASDAQ: AYTU ): Q2 GAAP EPS of -$2.15. Revenue of $26.28M (+13.6% Y/Y). Net revenue from the Company's Rx segment was $18.0 million during Q2 2023 compared to $14.6 million in the year ago quarter, growth of 23%. ADHD products (Adzenys XR-OD...
Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call Today at 5:00pm ET ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:...
ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results fo...
ENGLEWOOD, CO / ACCESSWIRE / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the delayed fili...
Aytu BioScience ( NASDAQ: AYTU ) is scheduled to announce FQ2 earnings results on Tuesday, February 14th, after market close. The consensus EPS Estimate is $0.20 and the consensus Revenue Estimate is $29.5M (+27.5% Y/Y). For further details see: Aytu BioScience FQ2 2023 ...
ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...